Patents by Inventor Andreas Schaubmar
Andreas Schaubmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110009317Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: June 2, 2010Publication date: January 13, 2011Inventors: Beat Amrein, Stefan Foser, Kurt Long, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Publication number: 20100210547Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: ApplicationFiled: April 27, 2010Publication date: August 19, 2010Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Publication number: 20100121036Abstract: Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: August 29, 2007Publication date: May 13, 2010Applicant: F. HOFFMANN-LA ROCHE AGInventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar
-
Publication number: 20100035817Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: ApplicationFiled: October 9, 2009Publication date: February 11, 2010Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Patent number: 7625996Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: GrantFiled: August 29, 2007Date of Patent: December 1, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Publication number: 20090252724Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.Type: ApplicationFiled: December 11, 2006Publication date: October 8, 2009Inventors: Hansruedi Loetscher, Walter Huber, Diana Schuhbauer, Karl Weyer, Manfred Brockhaus, Bernd Bohrmann, Hans Koll, Andreas Schaubmar, Kurt Lang
-
Patent number: 7541436Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: May 4, 2007Date of Patent: June 2, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Patent number: 7537755Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: August 15, 2007Date of Patent: May 26, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Patent number: 7531324Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: September 13, 2006Date of Patent: May 12, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Roberto Falkenstein
-
Patent number: 7531630Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: September 13, 2006Date of Patent: May 12, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Publication number: 20080171363Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: August 14, 2007Publication date: July 17, 2008Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20080119409Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: ApplicationFiled: August 29, 2007Publication date: May 22, 2008Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Publication number: 20080076710Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: May 4, 2007Publication date: March 27, 2008Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20080031853Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: August 15, 2007Publication date: February 7, 2008Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Patent number: 7318918Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: May 18, 2005Date of Patent: January 15, 2008Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Publication number: 20070225204Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 14, 2006Publication date: September 27, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070225205Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 14, 2006Publication date: September 27, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070025966Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: February 1, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070020734Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: January 25, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
-
Publication number: 20070020235Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: September 13, 2006Publication date: January 25, 2007Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLCInventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski